Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Incretin-based Treatment for Type 2 Diabetes Mellitus

제2형 당뇨병 환자에게 인크레틴 기반 약물치료요법

  • Kim, Hyun-Ah (College of Pharmacy, Seoul National University) ;
  • Kim, Hun-Sung (The Catholic University of Korea, Seoul St. Mary's Hospital)
  • 김현아 (서울대학교 약학대학) ;
  • 김헌성 (가톨릭대학교 서울성모병원)
  • Received : 2011.03.09
  • Accepted : 2011.06.03
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide delay gastric emptying, increasing satiety, and enhance insulin secretion. Two new classes of treatments related to incretin hormones for the management of type 2 diabetes mellitus have emerged: GLP-1 receptor agonists (e.g., exenatide, liraglutide) and the dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin, saxagliptin, vildagliptin, alogliptin), which prevent the degradation of GLP-1. A MEDLINE search was conducted in order to evaluate the efficacy and safety of incretin-based therapies and publications were reviewed. Data from clinical trials indicated incretin-based treatment showed clinically significant reductions in hemoglobin A1c with low risk of hypoglycemia. Weight reductions were observed with GLP-1 receptor agonists where as DPP-4 inhibitors are weight neutral.

Keywords

References

  1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53. https://doi.org/10.1016/S0140-6736(98)07019-6
  2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86. https://doi.org/10.1056/NEJM199309303291401
  3. Nathan DM, Buse JB, Davidson MB, et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203. https://doi.org/10.2337/dc08-9025
  4. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95. https://doi.org/10.2337/diacare.27.6.1487
  5. Kahn SE, Haffner SM, Heise MA, et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. https://doi.org/10.1056/NEJMoa066224
  6. Marchetti P, Lupi R, Del Guerra S, et al., Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care 2009;32 Suppl 2:S178-83. https://doi.org/10.2337/dc09-S306
  7. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124:S3-18. https://doi.org/10.1016/j.amjmed.2010.11.002
  8. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010;30:609-24. https://doi.org/10.1592/phco.30.6.609
  9. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84. https://doi.org/10.1592/phco.30.5.463
  10. Rodbard HW, Jellinger PS, Davidson JA, et al., Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59. https://doi.org/10.4158/EP.15.6.540
  11. Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009;29:55S-67S. https://doi.org/10.1592/phco.29.pt2.55S
  12. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35. https://doi.org/10.2337/diacare.27.11.2628
  13. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092- 100. https://doi.org/10.2337/diacare.28.5.1092
  14. Kendall DM, Riddle MC, Rosenstock J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91. https://doi.org/10.2337/diacare.28.5.1083
  15. Nauck MA, Duran S, Kim D, et al., A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin : a non-inferity study. Diabetologia 2007;50:259-67. https://doi.org/10.1007/s00125-006-0510-2
  16. Kim D, MacConell L, Zhuang D, et al., Effects of onceweekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93. https://doi.org/10.2337/dc06-2375
  17. Drucker DJ, Buse JB, Taylor K, et al., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50. https://doi.org/10.1016/S0140-6736(08)61206-4
  18. FDA MedWatch: The FDA Safety Information and Adverse Event Reporting Program Website. Available at http://www.fda.gov/Safety/MedWatch/default.htm
  19. Garber A, Henry R, Ratner R, et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, paralled-treatment trial. Lancet 2009;373:473-81. https://doi.org/10.1016/S0140-6736(08)61246-5
  20. Marre M, Shaw J, Brandle M, et al., Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78. https://doi.org/10.1111/j.1464-5491.2009.02666.x
  21. Nauck M, Frid A, Hermansen K, et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90. https://doi.org/10.2337/dc08-1355
  22. Zinman B, Gerich J, Buse JB, et al., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30. https://doi.org/10.2337/dc08-2124
  23. Buse JB, Rosenstock J, Sesti G, et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes; a 26- week randomized, parallel-groul, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47. https://doi.org/10.1016/S0140-6736(09)60659-0
  24. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7. https://doi.org/10.2337/dc06-0703
  25. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87. https://doi.org/10.2337/dc07-0627
  26. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71. https://doi.org/10.1007/s00125-006-0416-z
  27. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Clin Ther 2006;28:1556-68. https://doi.org/10.1016/j.clinthera.2006.10.007
  28. DeFronzo RA, Hissa MN, Garber AJ, et al., The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55. https://doi.org/10.2337/dc08-1984
  29. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drugnaive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86. https://doi.org/10.1111/j.1463-1326.2008.00876.x
  30. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41:368-73. https://doi.org/10.1055/s-0028-1104604
  31. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8. https://doi.org/10.1016/j.diabres.2006.12.009
  32. Rosenstock J, Kim SW, Baron MA, et al., Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85. https://doi.org/10.1111/j.1463-1326.2006.00698.x
  33. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-7. https://doi.org/10.2337/dc08-1035
  34. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55. https://doi.org/10.1111/j.1742-1241.2008.01933.x
  35. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-76. https://doi.org/10.1111/j.1463-1326.2008.01016.x
  36. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361-71. https://doi.org/10.1185/03007990903156111